Turn your patient data into trial-winning insights, instantly.

Leverage Inato's AI Patient Pre-Screening with EMR integration to highlight key patient data insights in your feasibility questionnaires, helping you stand out to sponsors.

Patient pre-screening table for Phase 3 Brinkamab severe asthma study showing six patients with their prescreening percentages and status: three to screen with 80-92%, two failed with 20-30%, and one to review at 10%.

Line chart showing a steady increase in patients pre-screened from December 29 to March 13, reaching a total of 35 patients.

Text highlighting top criteria for ineligibility as any other active disease or condition interfering with asthma assessment, with 31 patients excluded.

Interested in early access to this feature?

Please fill out the form below and our team will get in touch with you shortly.

*Only available on select studies